Additionally, a role for ceramide synthase-6 (CERS6) was recently uncovered in ALL, with CERS6 conferring resistance to BCL2 inhibitor ABT-737 [233]. The gene discussed is CERS6; the disease is acute lymphoblastic leukemia.